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Saliva: a biospecimen for non-invasive and 
accurate disease detection
Th e discovery that saliva contains molecular profi les that 
refl ect systemic diseases has opened the doors to a new 
non‑invasive diagnostic methodology: ‘salivary diag nostics’. 
Using saliva in diagnosis is not only practical and non‑
invasive, but at times is also proving to be more accurate 
than available alternatives. Th ese advantages might 
facilitate early detection of many diseases and improve 
clinical management.
Saliva comprises the secretions of the parotid, sub‑
mandibular and sublingual glands, hundreds of minor 
salivary glands and gingival crevice fl uid. Saliva functions 
include food digestion, bolus formation, lubrication and 
taste facilitation and immune‑related functions mediated 
by secreted antimicrobial peptides [1] and immuno‑
globulins [2]. However, these components constitute only 
a small part of saliva. Many molecular species have now 
been found, but their functions in the oral cavity remain 
largely unknown.
Cell‑free saliva (CFS) has been found to contain over a 
thousand proteins that are thought to be involved in a 
wide range of biological functions [3], as well as mRNA 
and microRNA (miRNA) transcripts [4‑6], and metabo‑
lites [7,8]. Detecting changes in the salivary concen‑
trations of these molecules has allowed the detection of 
oral and systemic diseases. Recent developments in 
genomic, proteomic and metabolomic approaches have 
facilitated sensitive and high‑throughput analysis of 
saliva and are proving increasingly useful for diagnostics. 
In this article, we review recent advances in the identi‑
fi cation of salivary biomarkers using these approaches, 
and the implications for diagnostic applications.
Saliva biomarker study design and clinical trial 
design
Early studies of salivary diagnostics for breast cancer 
assessed the use of proteins, including c‑erbB‑2 (human 
epidermal growth factor receptor 2, a receptor tyrosine 
kinase involved in cell growth), VEGF (vascular endo‑
thelial growth factor, a signal protein involved in vasculo‑
genesis and angiogenesis), EGF (epidermal growth factor, 
which promotes cell growth, division and diff erentiation), 
and CEA (carcinoembryonic antigen, a glycoprotein tumor 
marker involved in cell adhesion) [9‑13]. However, these 
studies investigated the presence of known serum bio‑
markers in saliva, rather than the potential existence of un‑
known biomarkers. Subsequently, de novo trans crip tomic, 
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proteomic and metabolomic approaches [5‑8,14‑17] have 
allowed the discovery and validation of salivary 
biomarker profiles for breast, oral, pancreatic and lung 
cancers, and periodontitis.
Stringent testing of biomarker performance, including 
verification and validation, is necessary before clinical 
application. Although there have been dramatic advances 
in biotechnology and biomarker research in the last 
decade, there have been relatively few successful clinical 
trials of biomarkers, compared with therapeutic research. 
Therapeutic research utilizes randomized placebo‑
controlled blinded clinical trials with internationally 
agreed standards in the evaluation of definitive clinical 
endpoints and outcomes. Analogous standards for bio‑
marker research did not exist until 2008 with the pro‑
posal of prospective specimen collection and retro‑
spective blinded evaluation (PRoBE) study design [18]. 
PRoBE incorporates prospective specimen collection 
from the target population, collected in a blinded fashion 
with no knowledge about patient outcomes. After out‑
come has been determined, patients and control subjects 
are selected randomly and their specimens tested. We 
expect that the application of PRoBE will greatly facilitate 
the transfer of salivary diagnostics to the clinic.
In the following sections we review recent advances 
made in the salivary biomarker field using genomic, 
epigenomic, transcriptomic, proteomic and metabolomic 
approaches. Tables 1 and 2 describe biomarkers that have 
been characterized and might be potentially useful for 
clinical applications.
The salivary genome and epigenome
Salivary genetic and epigenetic analysis provides insight 
into the presence of invading pathogens, and aberrant 
gene transcription profiles that directly reflect patho‑
logical genetic processes pertaining to, for example, 
cancers. This section discusses the most recent advances 
in genetic and epigenetic biomarker research. Table  1 
gives details of promising genetic and epigenetic salivary 
biomarkers reported for oral, and head and neck cancers.
The salivary genome consists of DNAs representing the 
genome of the individual, oral microbiota and infecting 
DNA viruses. The quality and yield of DNA that can be 
obtained from saliva is relatively good compared with 
blood and urine, can be used for genotyping, ampli fi‑
cation or sequencing [19], and can be stored long‑term 
without significant degradation [20]. As such, salivary 
DNA is a robust analyte for diagnostics, but is limited to 
reflecting presence or absence of specific genes, alteration 
to sequences (mutation) and methylation status, and 
cannot provide information on upregulation and down‑
regulation of gene expression.
The potential for salivary diagnosis of Epstein‑Barr 
virus (EBV)‑associated nasopharyngeal carcinoma (NPC) 
using quantitative PCR (qPCR) was reported in 2011 
[21]. This method achieved a detection rate of 80%, 
significantly less sensitive than serological methods 
(>90%). Also results were somewhat inconsistent with 
previous reports, as viral load was significantly higher in 
saliva post‑therapy compared with pre‑therapy. The 
authors suggested that this might have been due to 
decreased salivary flow rates caused by radiotherapy. 
However, higher levels of EBV DNA in T3/T4 stage NPC 
compared with T1/T2 stage NPC were reported, which is 
in agreement with other studies [21].
Aberrant methylation of tumor suppressor genes is 
common in cancer cells, and in oral squamous cell carci‑
noma (OSCC) hypermethylation has been linked with 
several cancer‑related alterations of dysplastic oral epi‑
the lium [22]. Promoter hypermethylation has been 
reported in premalignant OSCC lesions and in head and 
neck squamous cell carcinoma (HNSCC), showing 
poten tial as a biomarker for early detection of primary 
and relapsing OSCC or HNSCC [23‑28] (Table  1). 
Further more, methylation array analysis of DNA extracts 
from preoperative saliva, postoperative saliva, and tissue 
samples from patients with OSCC and from saliva from 
normal individuals showed significant differences in 
methylation patterns between preoperative and post‑
operative OSCC and between preoperative OSCC and 
control saliva samples. Gene panels were constructed 
that had low‑to‑moderate sensitivity and good‑to‑
excellent specificity for OSCC [27] (Table 1).
Quantitative methylation specific PCR (Q‑MSP) has 
shown promise for the development of biomarkers for 
HNSCC. Carvalho et al. [29] studied tumor‑suppressor 
gene hypermethylation in salivary rinses from pre‑treat‑
ment HNSCC patients using Q‑MSP. More than half of 
the study population was found to have methylation of at 
least one of the selected genes and had significantly 
reduced overall survival (Table  1). Early epigenetic 
attempts have been limited to approaches utilizing candi‑
date genes or cell‑culture‑based discovery, with valida‑
tion using well‑characterized pathology specimens from 
homogeneous cohorts. Guerrero‑Preston et al. [30] sought 
to overcome these limitations by using a new study 
design. To identify differentially methylated genes that 
could distinguish OSCC or HNSCC tumors from normal 
tissue, they used clinically defined samples from popu‑
lations with different risk profiles, high‑density promoter 
methylation platforms, publicly available expression 
arrays, two‑stage design (‘discovery screen’ and ‘preva‑
lence screen’) and Q‑MSP in a phase I biomarker 
development trial. This approach aims to improve phase I 
trials, so that only robust biomarkers are assessed in 
phase II trials. The discovery screen found that promoter 
methylation in KIF1A, HOXA9, NID2 and EDNRB genes 
had a moderate‑to‑substantial correlation with clinical 
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Table 1. Promising oral, and head and neck cancer salivary biomarkers discovered using epigenomics, transcriptomics, 
proteomics and metabolomics
   Sensitivity/ 
Approach  Markers specificity (%)/AUC
Epigenomics Candidate from previous study, Q-MSP analysis 
(HNSCC) [29]
DAPK, DCC, MINT-31, TIMP-3, p16, MGMT, CCNA1 NR
Candidate gene selection based on a previous 
study, Q-MSP discovery and validation (HNSCC) 
[23]
MINT31, CCNA1, DCC, DAPK, p16 34.1/91.8/0.63
MINT31, CCNA1, p16 24.0/97.1/0.61
Candidate from previous study, Q-MSP discovery 
and validation (HNSCC) [25]
KIF1A, EDNRB 77.4/93.1/NR
Candidate from previous study, Q-MSP 
assessment (HNSCC) [26]
EDNRB 65/51/0.61
Discovery by methylation array (OSCC) [27] GABRB3_E42_F, IL11_P11_R, INSR_P1063_R, NOTCH3_E403_F, 
NTRK3_E131_F, PXN_P308_F
77/83/NR
ADCYAP1_P455_R, CEBPA_P706_F, EPHA5_E158_R, FGF3_
E198_R, HLF_E192_F, IL11_P11_R, INSR_P1063_R, NOTCH3_
E403_F
69/96/NR
ERBB4_P255_F, IL11_P11_R, PTCH2_P37_F, TMEFF1_P234_F, 
TNFSF10_E53_F, TWIST1_P44_R
62/100/NR
Discovery with HumanMethylation27 DNA assay, 
validation with Q-MSP [30]
HOXA9, NID2 50/90/0.77
Transcriptomics Microarray discovery and qPCR validation (OSCC) 
[4]
IL8, IL1B, OAZ1, SAT 91/91/0.95
qRTPCR and ELISA validation of previously 
reported candidates [67]
IL-8, SAT, H3F3A, S100P 71/89/0.81
IL-8, IL-1B, SAT, OAZ1 79/77/0.86
IL-8, IL-1B, SAT, DUSP1 80/77/0.85
IL-8, IL-1B, S100P, OAZ1 64/86/0.78
IL-8, SAT, OAZ1, S100P 87/56/0.75
Discovery and validation by RT-preamp-qPCR 
(OSCC) [6]
miR-200a NR/NR/0.65
miR-125a NR/NR/0.62
Candidate gene selection based on previous 
study, qRT-PCR quantification [57]
miR-31 80/68/0.82
Proteomics Discovery by C4 RP-LC and capillary reversed-
phase LC with quadruple time-of-flight MS and 
validation by ELISA and immunoblotting (OSCC) 
[15]
M2BP, profilin, CD59, MRP14, catalase 90/83/0.93
ELISA assessment and qPCR confirmation [65] IL-8 86/97/0.98
Combination 
of proteomic/
transcriptomics
Reproducibility study of validated biomarkers 
using ELISA and qRT-PCR (OSCC) [46]
Proteins: IL-1B, IL-8 and M2BP
mRNAs: IL-8, IL-1B, SAT1, S100P
0.89/0.78/0.86, 
0.67/0.96/0.85, 
0.82/0.84/0.88 for 
OSCC total/T1-T2/T3-
T4 respectively
Metabolomics ULC/Q-TOF-MS (OSCC) [8] Valine, lactic acid 86.5/82.4/0.89
Discovery by CE-TOF-MS-based metabolomics [7] Taurine, piperidine and a peak at 120.0801 m/z NR/NR/0.87
AUC, area under curve; CE-TOF-MS, capillary electrophoresis time-of-flight mass spectrometry; ELISA, enzyme-linked immunosorbent assay; HNSCC, head and 
neck squamous cell carcinoma; LC, liquid chromatography; MS, mass spectrometry; NR, not reported; OSCC, oral squamous cell carcinoma; Q-MSP, quantitative 
methylation-sensitive PCR; qPCR, quantitative PCR; qRT-PCR, quantitative reverse transcription PCR; RT-preamp-qPCR, reverse transcription preamplification 
quantitative PCR; ULC/Q-TOF-MS, ultraperformance liquid chromatography coupled with quadruple/time-of-flight mass spectrometry; C4 RP-LC, C4 reversed-phase 
liquid chromatography.
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diagnosis. The prevalence screen showed a near perfect 
correlation between HOXA9 and NID2 promoter hyper‑
methylation and histological diagnosis. The combined 
analysis of these two genes resulted in 94% sensitivity, 
97% specificity and an area under the receiver operating 
characteristic curve (AUC) of 0.97 in tissue samples. 
However, the performance was far lower using saliva 
samples, with very low sensitivity [30] (Table 1).
The Human Oral Microbe Identification Microarray 
(HOMIM) has recently been developed comprising an 
oligonucleotide microarray based on 16S rRNA, and has 
allowed profiling and monitoring of changes in the oral 
microbiota [31]. Alterations in the oral bacterial profile 
have been found to correlate with several diseases, 
including pancreatic, oral and lung cancer [32], colonic 
neoplasia and extracolonic malignancy [33], cardiovas‑
cular and cerebrovascular disease [34‑36], and preterm 
birth [37], and these findings are being explored as 
potential salivary diagnostic approaches.
The salivary transcriptome
mRNAs and miRNAs are secreted from cells into the 
extracellular milieu and can be found in biofluids that are 
distant to the cellular sources [6,38,39]. In a diseased 
state, transcription of specific mRNAs and miRNAs is 
altered. Although the validity of salivary RNAs for the 
development of biomarkers with diagnostic potential 
initially received some criticism [40], this approach is 
now widely accepted. However, the precise sources of 
salivary RNAs and other molecules remain unclear (for 
further discussion see Box 1).
Standard procedures for salivary mRNA analysis 
previously required low temperatures and time‑consum‑
ing and costly mRNA isolation, which impeded clinical 
application. Now, simple methods of stabilizing mRNA in 
saliva samples have been developed, allowing room 
tempera ture storage without stabilizing agents, and 
sample analysis without further processing: so‑called 
‘direct‑saliva‑transcriptomic‑analysis’ [41]. However, this 
approach still involves centrifugation. An alternative 
method has been described [42], but was based on the 
use of a costly stabilizing agent. As such, neither method 
is completely practical for all applications. Salivary and 
plasma mRNAs can be surprisingly stable. The mecha‑
nism that confers such stability is currently unknown; 
however, AU‑rich element (ARE) sequence motifs in the 
3’ UTR regions of transcripts can recruit ARE‑binding 
proteins, thereby controlling stability [43].
Table 2. Promising salivary biomarkers for other diseases discovered using transcriptomics, proteomics and 
metabolomics
   Sensitivity/ 
Approach  Markers specificity (%)/AUC
Transcriptomics Affymetrix array discovery and qRT-PCR 
validation (pancreatic cancer) [5]
KRAS, MBD3L2, ACRV1, DPM1 90.0/95.0/0.97
Microarray discovery and qRT-PCR verification 
and pre-validation (lung cancer) [84]
CCNI, EGFR, FGF19, FRS2, GREB1 93.75/82.8/0.93
ELISA assessment (periodontal disease) [81] MIP-1α 94/92.7/0.94
Multiplex protein array discovery. Markers for 
distinguishing high and low responders to 
treatment for gingivitis (periodontal disease) 
[61]
IL-6, IL-8 NR/NR/0.81 (HR) and 
0.72 (LR)
Proteomics Two-dimensional gel electrophoresis and LC-
MS-MS (lung cancer) [59]
Calprotectin, AZGP1, haptoglobin hp2 88.5/92.3/0.9
Combination 
proteomic/
transcriptomic 
approaches
Discovery by 2D-DIGE and RT-PCR/Affymetrix, 
validation by qRT-PCR (breast cancer) [14]
mRNAs: CSTA, TPT1, IGF2BP1, GRM1, GRIK1, H6PD, MDM4, 
S100A8
Protein: CA6
83/97/92% accuracy
Metabolomics Discovery by CE-TOF-MS-based metabolomics 
(pancreatic cancer) [7]
Leucine with isoleucine, tryptophan, valine, glutamic acid, 
phenylalanine, glutamine, aspartic acid
NR/NR/0.99
Discovery by CE-TOF-MS-based metabolomics 
(breast cancer) [7]
NR NR/NR/0.97
Discovery by SERS (lung cancer) [17] Unidentified peak wavelengths; 822, 884, 909, 925, 1009, 
1,077, 1,369, 1,393, 1,721 cm-1
94/81/86% accuracy
AUC, area under curve; CE-TOF-MS, capillary electrophoresis time-of-flight mass spectrometry; ELISA, enzyme-linked immunosorbent assay; HR, high responder; 
LC-MS-MS, liquid chromatography-tandem mass spectrometry; LR, low responder; NR, not reported; qRT-PCR, quantitative reverse transcription PCR; RT-PCR, reverse 
transcription PCR; SERS, surface-enhanced Raman spectroscopy; 2D-DIGE, two-dimensional difference gel electrophoresis.
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Microarray technology has allowed high‑throughput 
saliva analysis and is the current gold standard for 
identifying saliva transcripts. The salivary transcriptome 
is profiled using microarrays and validated with qPCR. 
However, due to the low concentration of some bio‑
markers and occasional small sample volume, further 
innovations in technology have been required. Hu et al. 
[44] has overcome these limitations by two developments: 
a universal mRNA‑amplification method for microarray 
discovery, and a multiplex pre‑amplification method for 
qPCR validation. Moreover, the multiplex pre‑amplifi‑
cation method allows the simultaneous detection of 
many transcripts, providing cost‑effective screening and 
quantitative measurement using a relatively small amount 
of pre‑amplified product. In the following sections, we 
discuss advances in transcriptomic analysis of mRNAs 
and miRNAs using saliva samples.
mRNA
Characterization of mRNA profiles in body fluids 
provides insights into gene transcription in normal and 
disease states. There have been several advances in trans‑
criptomic salivary mRNA biomarker characterization in 
the last 4  years. As discussed in this section, salivary 
mRNA biomarkers have been pursued for a number of 
diseases, including OSCC, primary Sjögren’s syndrome, 
pancreatic cancer and ovarian cancer, and they have 
proved to be sensitive, specific and accurate.
Transcriptomic biomarkers for primary Sjögren’s 
syndrome have undergone preclinical validation [45], and 
mRNA biomarkers for OSCC previously discovered in a 
US cohort [4] have been found to detect OSCC in a 
cohort of different ethnicity [46]. Discovery and validation 
of transcriptomic salivary biomarkers has been per‑
formed for breast cancer using Affymetrix HG‑U133‑
Plus‑2.0 array discovery and preclinical validation in an 
independent cohort using RT‑qPCR [14]. Applying 
PRoBE design [18], Zhang et al. [5] identified salivary 
mRNA biomarkers for pancreatic cancer with excellent 
sensitivity and specificity. Importantly, these biomarkers 
could also distinguish pancreatic cancer from chronic 
pancreatitis with excellent sensitivity and specificity 
(both 96.7%). Also, the ovarian cancer salivary trans crip‑
tome profile was discovered in a clinical case controlled 
study using Affymetrix HG‑U133‑Plus‑2.0 array and then 
validated with qPCR by Lee et al. [47] (Table 2).
Recently, Spielmann et al. [48] used massively parallel 
sequencing to determine nucleotide sequences for each 
salivary RNA. The salivary transcriptome of unstimulated 
CFS and whole saliva (WS) from healthy human subjects 
was profiled: 25% of the sequences from CFS corres‑
ponded with the human genome and approximately 30% 
corresponded with the human oral microbiome. In CFS 
and WS, more than 4,000 genes and non‑coding 
functional sequences of human and microbial origin 
combined were detected.
miRNA
miRNAs are short (19 to 25 nucleotides) RNA transcripts 
associated with post‑transcriptional regulation by the 
RNA‑induced silencing complex [49,50]. These RNAs 
have been well characterized and found to play roles in 
cell growth, differentiation, apoptosis, pathogen‑host 
inter actions and stress responses and immune function, 
and are found in saliva [51‑53]. Just as with salivary 
mRNA, salivary miRNA is surprisingly stable, and this 
Box 1. Salivary biomarkers: where do they come from?
Accumulating evidence suggests that some salivary biomarkers could derive from systemic sources. Gao et al. [90] showed that altered 
salivary gland tissue production of transcription factors might account for a large proportion of upregulated and downregulated gene 
expression in the saliva of tumor-bearing mice, and that tumor-derived ectopic nerve growth factor could induce production of the 
transcription factor Egr-1 in salivary glands. Therefore, the salivary transcriptomic profile might be composed of transcripts originating in 
distant diseased tissues and transcripts originating in salivary glands, and altered expression levels of these transcripts might be caused by 
transcription factors originating in distant tissues.
Exosomes
Exosomes might be involved in transport of systemic biomarkers to saliva or transport of effectors of salivary gland transcriptional 
machinery from blood to the salivary glands. These membrane bound microvesicles of 30 to 100 nm in diameter and endocytic origin [91] 
are secreted by many cell types in diseased and non-diseased states. Exosomes contain protein, RNA and DNA, and have been found in 
most body fluids, including saliva [92-95]. Using in vitro methods, studies have shown that exosomes secreted from one cell can be taken 
up by other cells and can influence the receiving cell’s transcriptional signature [92,96,97]. Intercellular communication via exosomes can 
also occur between normal cells and cancer cells and between cancer cells and distant sites. This has been suggested as a mechanism 
by which cancer cells prepare distant sites for receiving metastatic cells [98,99]. Exosomes protect their contents from enzymatic 
degradation, suggesting a role in intercellular transport of molecules [6,97,100]. Similarities between serum and saliva biomarker profiles 
and the co-existence of exosomes in saliva and serum [101] also suggest the involvement of exosomes in transport of salivary biomarkers. 
Furthermore, a recent in vitro investigation showed that tumor-derived exosomes can interact with salivary gland cells and activate their 
transcriptional machinery [102].
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was recently reported to be due to it being harbored in 
exosomes [54] (also see Box 1).
miRNAs are differentially expressed in several cancer 
cell types compared with normal cells, with observed 
differences that range from ten to over a hundredfold. 
Changes in mRNA levels in cancer cells are comparatively 
small, and miRNA has been found to be more useful for 
characterizing solid tumor types than mRNA. miRNA 
has been shown to accurately distinguish poorly differ‑
entiated tumors, whereas mRNA profiling on the same 
samples produced highly inaccurate results [52,55,56]. 
Therefore, miRNA cancer biomarkers are potentially very 
powerful, and if miRNA‑based approaches also reveal 
similarly differential profiles using saliva samples they 
may become very useful in salivary diagnostics.
Park et al. [6] found significantly reduced levels of 
miRNAs miR‑125a and miR‑200a (known tumor sup‑
pres sors) in the saliva of oral cancer patients compared 
with controls. Recent work has also shown that salivary 
miR‑31 (implicated in tumorigenesis) was significantly 
elevated in all stages of oral cancer, and that salivary 
miR‑31 was more abundant than blood miR‑31, indicat‑
ing the oral tumor origin of this biomarker [57].
The salivary proteome
The use of surface‑enhanced laser desorption/ionization 
time‑of‑flight (SELDI‑TOF) mass spectrometry (MS), 
which allows rapid, high‑throughput detection of proteins 
in minute sample volumes without pre‑processing, has 
been reported for several diseases [58]. Recently, analysis 
of saliva for protein biomarker discovery has mainly been 
performed using two‑dimensional difference gel electro‑
phoresis (2D‑DIGE) coupled with MS (which can identify 
around 300 proteins in a sample [59]), and liquid chroma‑
tograpy‑MS (LC‑MS) based techniques (which can 
identify more than 1,050 proteins in a sample; reviewed 
in [60]). Thus, liquid chromatographic separation appears 
to resolve protein species more precisely than gel 
electrophoresis methods. Recently, a multiplex protein 
array was also employed, providing high‑throughput 
analysis [61]; however, this method requires some prior 
knowledge of likely analytes.
Despite these advances, the discovery and validation of 
salivary protein biomarkers provide challenges. Proteins 
generally have short half‑lives, although there can be 
large differences in observed stability. Both the nature of 
peptides and the milieu of the oral cavity make salivary 
proteins vulnerable to degradation. Thus, protein‑based 
salivary diagnostics require immediate processing and/or 
analysis of saliva samples, or the use of freezers and costly 
protease inhibitors. In a research setting, these require‑
ments can be easily met. However, in clinical settings 
protein stabilization without freezers and specialized 
machinery may be required. Our laboratory has 
developed protein stabilization methods that allow 
storage of saliva samples at room temperature, without 
the need for expensive reagents and equipment [62,63].
Several different classes of salivary protein biomarkers 
have been reported. Endothelin‑1, a vasoconstrictor, was 
reported as a potential biomarker for OSCC development 
in patients with oral lichen planus [64]. Interleukins IL‑8 
and IL‑1β, glycoprotein M2BP (thought to be involved in 
natural killer cell activity enhancement, tumor suppres‑
sion, interleukin production and cell aggregation), 
profilin (actin‑binding protein, important for temporal 
and spatial control of actin microfilament growth), CD59 
(complement regulatory protein), MRP14 (a protein 
involved in regulating myeloid cell function) and catalase 
(catalyses the conversion of hydrogen peroxide to water 
and oxygen) have been reported as salivary biomarkers 
for oral cancer [15,65‑69], and immunoglobulins have 
long been described as salivary biomarkers for HIV 
infection [70,71].
The salivary metabolome
The metabolome is the complement of small‑molecule 
metabolites. Similar to the transcriptome and proteome, 
the metabolome changes continually and any single 
profile is a snapshot reflecting gene and protein expres‑
sion. Metabolomic investigations can generate quantita‑
tive data for metabolites in order to elucidate metabolic 
dynamics related to disease state and drug exposure [72].
Using capillary electrophoresis time‑of‑flight MS, 
Sugimoto et al. [7] identified metabolites for detecting 
oral, breast and pancreatic cancer, and periodontal 
disease. Multiple logistic regression models yielded 
AUCs of 0.865 for oral cancer, using a profile consisting 
of three oral‑cancer‑specific metabolites: taurine, piperi‑
dine and a peak with a mass‑to‑charge ratio (m/z) of 
120.0801. A breast cancer profile consisting of taurine 
and lysine achieved an AUC of 0.973. A model consisting 
of a pancreatic‑cancer‑specific metabolite signature com‑
pris ing leucine with isoleucine, tryptophan, valine, 
glutamic acid, phenylalanine, glutamine and aspartic acid 
achieved an AUC of 0.993. Periodontal diseases achieved 
an AUC of 0.969 using a panel of only two markers, but 
the specific markers were not reported [7] (Tables 1 and 
2). Using ultraperformance LC with quadrupole/time‑of‑
flight MS and multivariate statistical analysis, Wei et al. 
[8] demonstrated that a salivary metabolic profile com‑
prising valine, lactic acid and phenylalanine could discri‑
mi nate OSCC from controls and oral leukoplakia with 
good‑to‑excellent sensitivity, specificity and accuracy 
(Table  1). However, a limitation of metabolomics com‑
pared with genomics, transcriptomics and proteomics is 
the inability at times to specifically identify the differ‑
entially expressed metabolites, as exemplified by these 
findings [7,8,17] (Tables 1 and 2).
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Salivary diagnostics
Early‑stage disease detection is imperative for successful 
therapy for most cancers, and the ability to quickly 
identify suspicious lesions will also greatly reduce 
hospital burdens. In the future, salivary diagnostics is 
expected to facilitate rapid, easily accessible and non‑
invasive clinical diagnosis, thus allowing more cases of 
disease to be detected at early stages and decreasing 
mortality caused by oral and systemic cancers, and 
infectious diseases.
Oral disease detection
Since the 1990s salivary diagnostics have been developed 
for oral diseases, allowing monitoring of periodontal 
disease and assessment of caries risk [73‑75]. In recent 
years there have been many reports of potential salivary 
biomarkers for periodontal diseases found by candidate 
approaches, and conventional proteomics has been found 
to be highly accurate for detecting periodontitis as well as 
oral, head and neck cancers.
Several candidate approaches have elucidated bio‑
markers for periodontitis and responses to therapy. 
Gursoy et al. [76] compared the concentration of five 
specific salivary proteins, and the presence of five oral 
pathogens in patients with advanced periodontal disease 
and healthy controls. They found an association of IL‑1β 
and oral pathogens with periodontitis. Using enzyme‑
linked immunosorbent assay (ELISA), patients with 
chronic periodontitis were found to exhibit significantly 
lower IL‑17 and significantly higher IL‑18 saliva concen‑
trations compared with healthy individuals [77].
In a response to therapy study, salivary biomarkers for 
periodontitis were assessed in adults with chronic perio‑
dontitis, in which 33 participants received oral hygiene 
instructions alone and 35 participants had conventional 
periodontal treatment comprising scaling and root 
planning combined with oral hygiene instructions. Saliva 
samples collected at intervals were analyzed for several 
proteins, and it was found that the levels of IL‑1β, 
macrophage inflammatory protein 1α (MIP‑1α, a chemo‑
kine produced by macrophages after bacterial endotoxin 
stimulation, which activates granulocytes), matrix 
metalloproteinase‑8 (MMP‑8, a collagen cleaving enzyme 
found in connective tissue and involved in degradation of 
extracellular matrix in both normal and disease 
processes) and osteoprotegerin (OPG, a decoy receptor 
that reduces the production of osteoclasts) detected in 
saliva reflected disease severity and response to therapy 
and may have potential use in monitoring periodontal 
disease [78].
Nomura et al. [16] found that a combination of alanine 
aminotransferase (a transaminase that catalyses two steps 
of the alanine cycle) level and Porphyromonas gingivalis 
ratio could indicate periodontal disease progression with 
40% sensitivity and 96% specificity. Lee et al. [61] 
analyzed saliva samples using a multiplex protein array 
for selected biomarkers implicated in host defense, 
inflam mation, tissue destruction and angiogenesis, and 
measured subgingival bacterial proportions by checker‑
board DNA‑DNA hybridization. The authors devised a 
system to discriminate ‘high’ and ‘low’ responders to 
treatment for gingivitis. Salivary IL‑6 and IL‑8 levels 
provided the best distinction between high and low 
responders (Table 2).
Proteomic and microbial studies have been used to 
successfully identify biomarkers for periodontal disease. 
Choi et al. [79] searched for potential protein biomarkers 
for periodontitis in gingival crevicular fluid using LC‑
tandem MS (LC‑MS‑MS). Azurocidin (an antibiotic 
protein of azurophil granules with chemotactic activity) 
was identified as upregulated in gingival crevicular fluid, 
but not in saliva. ELISA was then used to verify up‑
regulation of azurocidin, identifying the latter as a candi‑
date biomarker for inflammatory periodontal disease 
[79]. Using SELDI‑TOF MS, Hart et al. [80] characterized 
the oral flora and salivary proteome in caries‑free and 
caries‑active children, and found that a combination 
model of microbial‑proteomic data was far more accurate 
than microbial or proteomic models alone. Their best 
model had a 6% test error, with >92% sensitivity, and 
>95% specificity.
Al‑Sabbagh et al. [81] investigated salivary levels of 
bone‑remodeling‑related molecules in chronic perio‑
dontitis patients using ELISA. MIP‑1α levels were found 
to be 18‑fold higher in periodontitis patients than normal 
and clinical measures correlated significantly with MIP‑
1α levels, and achieved excellent sensitivity, specificity 
and accuracy (Table 2). In a study of dysplastic oral 
leukoplakia in relation to tobacco habits and perio‑
dontitis, Sharma et al. [82] found that increasing IL‑6 
levels correlated with increasing severity of dysplasia.
Discovery and validation of salivary biomarkers for 
OSCC followed, and has also been confirmed across 
ethnic backgrounds [46]. Many salivary biomarkers, 
identi fied using candidate as well as ‘omic approaches 
(including metabolomic, transcriptomic (miRNA and 
mRNA), proteomic, epigenomic and microbial) have 
been described for oral, and head and neck cancers 
[4,6‑8,22,23,25‑29,46,57,64,65,67,83].
A comparison of salivary biomarkers for OSCCs and 
HNSCCs can be seen in Table  1. Several single marker 
candidates for OSCC have been reported, including 
EDNRB gene (which encodes endothelin receptor type B, 
a G‑protein‑coupled receptor that activates a phos pha‑
tidyl inositol‑calcium second messenger system) hyper‑
methy lation [25,26], miRNAs miR‑200a, miR‑125a and 
miR‑31 [6,57], and IL‑8 protein [65], but only IL‑8 has 
been shown to be a sensitive, specific and accurate single 
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marker for OSCC and could prove to be a cost‑efficient 
analyte for OSCC detection.
Several biomarker panels have also been investigated 
for OSCC detection. An mRNA panel has been validated 
with excellent sensitivity, specificity and accuracy and 
could be considered ‘second place’ to IL‑8 [67]. Interest‑
ingly, proteomic‑transcriptomic combination panels have 
achieved good sensitivity, specificity and accuracy, but 
are lagging behind the transcriptomic panel in these 
performance measures [46]. A five‑protein panel achieved 
higher sensitivity, lower specificity and similar accuracy 
to IL‑8 alone [15]. Metabolomic markers for OSCC have 
also achieved good accuracy, but have not been validated 
[7,8]. Many epigenetic salivary biomarker panels have 
been reported and some have achieved 100% specificity, 
but accompanied by low sensitivity (62% [27]; Table  1), 
and have not been as stringently tested as proteomic and 
transcriptomic biomarkers.
Systemic disease detection
More recently, advances in biotechnology, genomics and 
proteomics have extended the range of salivary 
diagnostics to systemic disease monitoring. Possibly the 
most attractive attribute of salivary diagnostics is its 
implication in systemic disease diagnosis, due to the 
invasive nature and in some cases poor accuracy of 
current standard diagnostic methods [5].
Available tests for systemic cancers include invasive 
and expensive procedures (such as magnetic resonance 
imaging, biopsy, X‑ray, computed tomography scan, 
exfoliative cytology, positron emission tomography scan 
and endoscopy). This, combined with significantly worse 
prognosis associated with late diagnosis, makes the 
prospect of salivary diagnostics particularly valuable in 
oncology. Available diagnostic methodologies for other 
systemic diseases, such as infections, have similar 
problems. In this section, we will discuss progress in the 
use of salivary biomarker‑based approaches for diagnosis 
of pancreatic cancer, lung cancer and breast cancer and 
finally other systemic diseases.
Pancreatic cancer
A significant milestone in salivary diagnostics was reached 
by Zhang et al. [5], with a prospective sample collection 
and retrospective double‑blinded validation study that 
showed that a salivary transcriptome profile could detect 
early stage resectable pancreatic cancer. The use of the 
salivary transcriptome for detecting pancreatic cancer 
was also found to outperform currently used blood‑based 
tests in terms of sensitivity and specificity, but did not 
allow sensitive detection of pancreatitis, unlike some 
blood‑based tests. Farrell et al. [32] showed that varia‑
tions in oral microbiota could possibly be used to detect 
pancreatic cancer and pancreatitis. Also, a metabolomic 
approach [7] has identified pancreatic‑cancer‑specific 
salivary metabolomic biomarkers that could distinguish 
pancreatic cancer from oral and breast cancer and 
normal controls. Although both the transcriptomic and 
the metabolomic biomarkers achieved excellent accuracy 
for this disease, only the transcriptomic panel has been 
validated (Table 2).
Lung cancer
Currently, lung cancer may be detected with chest X‑ray 
and computed tomography, and diagnosis is confirmed 
via biopsy. Thus, lung cancer detection is limited by stage 
of disease, and more than 75% of cases are diagnosed in 
the late stages, significantly reducing survival rate. Lung 
cancer is often asymptomatic or presents with non‑
specific symptoms, so there is considerable need for non‑
invasive approaches for earlier detection of disease 
[59,84].
Using 2D‑DIGE and MS, Xiao et al. [59] performed 
proteomic analysis of saliva samples from lung cancer 
patients. Sixteen candidate biomarkers were discovered 
and further verified. Three candidate markers (calpro‑
tectin, a calcium and zinc binding protein, zinc‑α‑2‑
glyco protein, a lipolysis stimulating protein, and hapto‑
globin hp2, a protein that binds free plasma hemoglobin) 
achieved good sensitivity and excellent specificity and 
accuracy (Table 2).
Zhang et al. [84] profiled the salivary lung cancer 
transcriptome and discovered and pre‑validated a panel 
of seven highly discriminatory mRNAs: BRAF (which 
encodes the protein B‑Raf, and is involved in directing 
cell growth), CCNI (which encodes the protein cyclin‑I, 
and binds activated cyclin‑dependant kinase 5), EGFR 
(epidermal growth factor receptor), FGF19 (fibroblast 
growth factor 19, involved in many biological processes, 
including morphogenesis and cell growth, and tumor 
growth and invasion), FRS2 (fibroblast growth factor 
receptor substrate 2, an adapter protein that links fibro‑
blast growth factor and nerve growth factor receptors to 
downstream signaling pathways), GREB1 (growth regu‑
lation by estrogen in breast cancer 1, an early response 
gene in the estrogen receptor pathway), and LZTS1 
(leucine zipper putative tumor suppressor 1, a putative 
tumor suppressor gene). A panel consisting of five of 
these markers differentiated lung cancer from normal 
subjects with 93.75% sensitivity and 82.81% specificity 
(Table 2).
Surface‑enhanced Raman spectroscopy (SERS) was 
recently employed by Li et al. [17] to identify biomarkers 
for lung cancer. SERS revealed nine peaks (assigned to 
amino acids and nucleic acid bases) that could distinguish 
samples from patients with lung cancer and controls with 
86% accuracy, 94% sensitivity and 81% specificity. Thus, 
for lung cancer, both transcriptomic and proteomic 
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approaches are proving highly useful for biomarker 
develop ment, and metabolomic approaches are also 
showing promise (Table 2).
Breast cancer
Today, breast cancer detection employs physical exami‑
na tion and imaging techniques. Emerging technologies 
such as molecular analysis of nipple fluid aspirate and 
ductal lavage samples [85] provide improved accuracy 
and potentially earlier diagnosis, but are invasive and 
limited to high‑risk patients. Several earlier studies indi‑
cated the potential for salivary proteomic detection of 
breast cancer and its potential use in monitoring res‑
ponse to treatment, and the use of single markers, such 
as salivary protein c‑erbB‑2, has also been investigated 
[9‑12].
Cao et al. [86] investigated the salivary proteome of 
breast cancer patients compared with healthy individuals. 
Saliva samples were analyzed with isobaric tags for 
relative and absolute quantitation (iTRAQ) technology 
coupled with LC‑MS‑MS. Of 464 identified proteins, 9 
were associated with breast cancer and had a 1.5‑fold up‑
regulation or downregulation. Recently, preclinical 
valida tion of transcriptomic and proteomic salivary bio‑
markers with diagnostic power for breast cancer or 
ovarian cancer has also been reported [14,47]. However, 
the metabolomic approach to breast cancer detection has 
shown better results than the combination proteomic‑
transcriptomic approach in terms of accuracy (Table 2).
Other systemic diseases
Advances in the use of salivary biomarkers for detecting 
autoimmune diseases, systemic microbial infections and 
diabetes have been described recently [2,45,70,87]. 
Menezes et al. [88] investigated hepatitis C virus (HCV) 
loads in saliva and serum samples from HCV‑infected 
individuals using qPCR, and found that HCV RNA could 
be consistently detected in saliva of HCV‑infected 
individuals, although at significantly lower levels than in 
serum.
Border et al. [89] performed label‑free differential 
protein expression analysis using multidimensional LC‑
MS‑MS to characterize the proteome of saliva collected 
from edentulous type 2 diabetic patients compared with 
non‑diabetic controls. Several proteins, PLUNC (palate, 
lung and nasal epithelium carcinoma‑associated protein, 
a secretory protein expressed in the upper airways and 
nasopharyngeal regions), GAPDH (glyceraldehyde‑3‑
phosphate dehydrogenase, an enzyme that catalyses the 
sixth step of glycolysis), SAA (serum amyloid A, an 
adipolipoprotein associated with high density lipopro‑
teins in plasma), serotransferrin (an iron‑binding trans‑
port protein), PIP (prolactin‑induced protein, an aspartyl 
protease that inhibits T‑lymphocyte programmed cell 
death), A2MG (α2‑macroglobulin, a broad protease inhi‑
bitor), and cystatin S and cystatin SN (protein inhibitors 
of cysteine proteinases), were found to have diagnostic 
potential for type 2 diabetes but require further testing to 
determine clinical value.
Concluding remarks
The use of saliva as a diagnostic specimen avoids the 
pain, anxiety and infection risk associated with tradi‑
tional methods of specimen collection, such as blood 
sampling or tissue biopsy. Saliva sampling also facilitates 
the collection of multiple subsequent samples for disease 
monitoring. Processing and analysis of saliva is also much 
easier than blood and other samples. Unlike blood, saliva 
does not clot and salivary analytes are very stable. 
Analytes must be cost efficiently and easily stabilized for 
Figure 1. Clinical context of salivary diagnostics. Salivary 
diagnostics could reduce the number of unnecessary referrals to 
hospital for invasive, time-consuming and expensive diagnostics. 
An example situation is shown (with examples of percentages of 
patients that might be involved in parentheses) for the use of a saliva 
biomarker (Bx) test, in which a health professional, such as a dentist, 
observes a suspicious oral lesion. This is followed by screening of 
saliva, and if appropriate, referral to a specialist. Salivary diagnostics 
using clinically validated biomarkers can be implemented in the 
early stages of the clinical management hierarchy (green arrow and 
box), thus significantly reducing unnecessary referrals to specialists 
and unnecessary biopsies seen in current clinical approaches, where 
management follows the black arrows exclusively and results in high 
(such as 96%) negative test rates at biopsy (Bx-; red circle).
General population 
General dentist offices 
Saliva biomarker test 
Bx+ cancer (1%)
Bx+ dysplasia (3%)
 
 
Persistent lesion 
Suspicious oral lesion (10%) 
Oral medicine/oral surgery clinics 
Oral cancer 
Head and neck oncology clinic 
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storage until analysis or transport to the laboratory. 
Technologies for saliva sampling and stabilization, and 
point‑of‑care technology that can allow accurate detec‑
tion of biomarkers without any processing of saliva 
samples are currently available or being developed. Using 
such approaches, salivary diagnostics could be performed 
without the need for specially trained professionals or be 
incorporated as part of primary healthcare, greatly 
reducing burdens on hospitals relating to costly, complex 
and invasive diagnostic procedures (Figure 1). However, 
most reports on individual biomarkers and multiple 
biomarker panels have been only preliminary and require 
further validation before testing at the clinical level.
Transcriptomic and proteomic approaches to bio‑
marker development have so far had the most progress 
towards clinical testing. Salivary biomarkers for a range 
of cancers, both local and distant to the oral cavity, have 
been characterized and validated at the pre‑clinical level. 
Certainly, salivary biomarkers for oral diseases such as 
OSCC are likely to become clinically implemented before 
those for systemic cancers, as they have been well 
described and validated and often originate locally to the 
oral cavity where the biospecimen is collected, lending 
legitimacy to such biomarkers.
The transfer of scientific knowledge of salivary bio‑
markers to clinical applications is a challenging process 
that has rarely resulted in clinical implementation. 
Under standing the sources of salivary biomarkers (for 
example, exosomes; Box 1) will be a significant objective 
in the development of salivary diagnostics, as this will 
provide the rationale for the use of salivary biomarkers 
for systemic diseases. Our group and others continue to 
investigate the mechanisms by which salivary biomarkers 
appear in saliva, and to develop technologies for 
detecting biomarkers with high sensitivity and specificity 
in pursuit of compliance at the FDA level.
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